Patrick J. Haley - Feb 3, 2022 Form 4 Insider Report for EXELIXIS, INC. (EXEL)

Role
EVP, Commercial
Signature
/s/ Christopher J. Senner, Attorney in Fact
Stock symbol
EXEL
Transactions as of
Feb 3, 2022
Transactions value $
-$960,600
Form type
4
Date filed
2/4/2022, 08:52 PM
Previous filing
Dec 17, 2021
Next filing
Feb 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXEL Common Stock Options Exercise $114K +60K +24.47% $1.90* 305K Feb 3, 2022 Direct F1
transaction EXEL Common Stock Sale -$1.07M -60K -19.66% $17.91 245K Feb 3, 2022 Direct F2, F3
holding EXEL Common Stock 23.5K Feb 3, 2022 By spouse
holding EXEL Common Stock 10.6K Feb 3, 2022 By 401(k) F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EXEL Option (right to buy) Options Exercise $0 -60K -100% $0.00* 0 Feb 3, 2022 Common Stock 60K $1.90 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 136,748 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F2 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2021.
F3 Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.76 to $18.04. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4 Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of February 2, 2022.
F5 The option, representing the right to purchase a total of 85,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.